Professional Documents
Culture Documents
Clinical Features
The clinical features of RAS comprise recurrent bouts of
one or several rounded, shallow, painful oral ulcers at
intervals of a few months to a few days; RAS has three
main presentations: minor (MiRAS), major (MaRAS), or
herpetiform (HU) ulcers (Table 1).
Minor recurrent aphthous stomatitis (MiRAS), the
most common variety, affects about 80% of RAS adult
and child patients, and is characterized by round or
oval shallow ulcers usually less than 5 mm in diameter
with a gray-white pseudomembrane enveloped by a
thin erythematous halo. Usually, MiRAS occurs on the
nonkeratinized mobile surfaces such as the labial and
buccal mucosa and floor of the mouth and is uncommon on the gingiva, palate, or dorsum of the tongue.
These lesions heal within 1 to 2 weeks without scarring.5
Major recurrent aphthous stomatitis (MaRAS) is an
uncommon and severe form of RAS, comprising oval or
irregular ulcers that may exceed 1 cm in diameter.
These ulcers have a predilection for the lips, soft palate,
and fauces (but can affect any site), persist for up to 6
weeks, and often heal with scarring.
Herpetiform (HU) is very uncommon, being characterized by multiple recurrent crops of small, painful
ulcers that may be distributed throughout the oral cavFrom the Eastman Dental Institute for Oral Health Care Sciences,
University College London, London, England.
Address correspondence to Stephen R. Porter, M.D., Department of Oral
Medicine, University College London, University of London, 256 Grays Inn
Road, London WC1X 8LD UK.
2000 by Elsevier Science Inc. All rights reserved.
655 Avenue of the Americas, New York, NY 10010
Hematinic Deficiency
Several studies from the UK, United States, and Spain
have demonstrated that hematinic deficiency (iron, folic
acid, or vitamin B12) are twice as common in RAS
patients than in controls.38 46 About 20% of patients
with RAS may have a hematinic deficiency, though one
U.S. study did not report any hematinic problem.47
Vitamin B1, B2, and/or B6 deficiency was observed in a
cohort of Scottish patients with RAS.48
Gluten-Sensitive Enteropathy
Less than 5% of outpatients who initially present with
RAS49 51 are prone to have gluten-sensitive enteropathy
(GSE: celiac disease). These RAS patients may not always have gastrointestinal symptoms or other clinical
features suggestive of GSE but usually have folate de0738-081X/00/$see front matter
PII S0738-081X(00)00147-4
Clinics in Dermatology
Table 1.
2000;18:569 578
Sex ratio
Age of onset (years)
Number of ulcers
Size of ulcers (mm)
Duration (days)
Rate of recurrence (months)
Sites
Permanent scarring
Minor
Major
Herpetiform
MF
519
15
10
414
14
Lips, cheeks, tongue,
floor of mouth
Uncommon
MF
1019
110
10
30
Monthly
Lips, cheeks, tongue,
palate, pharynx
Common
F M(?)
2029
10100
12*
30
Monthly
Lips, cheeks, tongue, pharynx,
palate, gingiva, floor of mouth
Uncommon
Food Hypersensitivities
Some studies have noted an increased prevalence of
atopy among RAS patients,60,61 but others have failed to
find any significant correlation.62 Some patients correlate the onset of their ulcers to exposure to certain
foods, but controlled studies have failed to disclose a
causal role despite the fact that certain foods triggering
positive skin-prick reactions will elicit pain when they
are topically applied to aphthous ulcers.63,64 Dietary
manipulation significantly improves RAS in only rare
instances.65
Zinc Deficiency
Any association between RAS and zinc deficiency
seems tenuous.66
Menstrual Change
A minority of women with RAS have cyclical oral ulceration related to the luteal phase of the menstrual
cycle. Nevertheless, a detailed review of all pertinent
literature failed to find any association between RAS
and altered female sex corticosteroids.6770 A link with
autoimmune progesterone dermatitis is most unlikely.71
Psychological Illness
Psychological illness has been proposed to initiate some
episodes of RAS, but there are sparse data to suggest a
Genetic Factors
Recurrent aphthous stomatitis may have a familial basis, perhaps more than 40% of RAS patients having a
vague family history of oral ulceration. Patients with a
positive family history of RAS may develop oral ulcers
at an earlier age and have more severe symptoms than
those with no such history.77,78 There is an increased
likelihood of a child developing RAS if both parents
have ulcers, and there is a high correlation of RAS in
identical twins.79,80 Nevertheless, no consistent significant association between RAS and a particular serologically determined HLA antigen or haplotype has been
demonstrated (reviewed elsewhere).5 This may reflect
inadequate patient numbers and/or variable ethnic
backgrounds of investigated patients, or most likely the
lack of any immunogenetic basis to RAS.
Clinics in Dermatology
2000;18:569 578
Topical corticosteroids
Antibiotics
Immunomodulators
Viruses
An association of RAS with adenoviruses has been
suggested,98 100 but adenoviruses are ubiquitous organisms. The possible association of RAS with herpesviruses-1 6 is reviewed elsewhere.101 Herpesvirus virions
are not demonstrable in RAS,102105 and although RNA
complimentary to herpes simplex virus (HSV) has been
detected in circulating mononuclear cells in some RAS
patients106 and in circulating immune complexes,107 serum levels of interferon are not increased,108 HSV is not
demonstrable in RAS lesions,109,110 and RAS patients are
not always HSV seropositive.111
There is contradictory serological and molecular biological data on the frequency of detection of cytomegalovirus and varicella zoster infection in patients with
RAS,112115 and there is little substantive data to suggest
that anti-herpesvirus antivirals such as acyclovir are of
therapeutic benefit in the management of RAS.116,117
An association between Epstein-Barr virus (EBV)
and the early ulcerative lesions of RAS and Behcets
disease has been proposed, but the data are based upon
a very small group of patients.118 Human herpesvirus-6
(HHV-6) DNA has not been detected in 6 of 21 RAS
lesions115 and 95% of the patients had IgM antibodies to
HHV-6,114 but both HHV-6 and HHV-7 DNA are rarely
detected in peripheral blood moncytes of RAS patients
with and without ulceration.119
Immunopathogenesis
A review of the immunology and possible pathogenesis
of RAS is beyond the scope of this clinical review. A
detailed discussion of this subject can be found elsewhere.5
571
Others
Chlorhexidine gluconate
Benzydamine hydrochloride
Carbenoxolone disodium
Betadine
Hydrocortisone hemisuccinate
Triamcinolone acetonide
Flucinonide
Betamethasone valerate
Betamethasone-17-benzoate
Flumethasone pivolate
Beclomethasone dipropionate
Sucralphate
Topical tetracyclines
Levamisole
Transfer factor
Colchicine
Gammaglobulins
Azathioprine
Dapsone
Thalidomide
Pentoxifylline
Prednisolone
Azelastine
Alpha-2-inteferon
Cyclosporine
Amlexonox
5-Aminosalicyclic acid
Systemic zinc sulphate
Monoamine-oxidase inhibitors
Sodium cromoglycate
Deglycyrrhizinated licorace
Etretinate
Low-energy laser
Management of RAS
A systematic review of the management of RAS is
available.128 Patients with oral ulceration possibly associated with systemic disease require referral to an appropriate specialist.5 All patients should be advised to
use an oral hygiene procedure that is as atraumatic as
possible, and all dental appliances should fit well and
be non-tissue-damaging.
Hematinic Replacement
The correction of any hematinic deficiency is of limited
benefit unless the cause is corrected.129 Zinc sulphate
therapy is not effective,130 and LongoVital, a herbalbased vitamin tablet with a wide range of trace elements, seems to be of limited benefit.131
Topical Antimicrobials
Chlorhexidine used as a 0.2% w/w mouthrinse or 1%
gel can reduce the duration of ulcers and increase the
number of ulcer-free days.132135 (Table 2) One study,
however, found little objective value of chlorhexidine
gluconate mouthrinse over placebo in the management
of RAS.136 Regular use of chlorhexidine gluconate may
Clinics in Dermatology
Topical Corticosteroids
Topical corticosteroids remain the mainstay of RAS
treatment in most countries,142 although there are few
well-controlled studies of their precise efficacy.128 A
wide range of different topical corticosteroids may reduce symptoms.143150
Topical Analgesics
Benzydamine hydrochloride mouthwash is of no more
benefit on ulcer healing than placebo194; nevertheless, it
(or lignocaine gel) can produce transient relief of pain.
Toothpastes
Toothpastes that enhance the salivary peroxidase system are not effective.141,151,152 It has been suggested that
elimination of sodium lauryl sulphate (SLS) can reduce
or prevent RAS,153 but although one later study confirmed this,154 another did not.155
2000;18:569 578
Physical Therapies
Surgical removal, debridement, or laser ablation of ulcers is not practical and is of very limited practical
benefit.173175 The efficacy of a chemical cautery agent
(Debacterol) is unclear.176
Systemic Therapies
Systemic immunosuppression is sometimes warranted
in view of the limited efficacy of topical agents, and the
sometimes profound pain and/or long-standing ulceration; however, whereas many such agents have been
proposed to be clinically useful, there is little evidence
base.
Levamisole
Levamisole rarely causes objective clinical improvement,179 and the associated adverse effects (nausea, hyperosmia, dysgeusia, and agranulocytosis) discourage
its use.180 186
Colchicine
Colchicine has proved clinically beneficial when investigated in small groups of patients with RAS,187,188 and
in an open study of 20 patients, colchicine (1.5 mg/day
for 2 months) caused a significant reduction in pain
scores and frequency of self-reported ulcers.189 Unfortunately, not all patients benefit from colchicine therapy, and at least 20% can have painful gastrointestinal
symptoms or diarrhea.189 Long-term use can induce
infertility in young men. Combined colchicine and thalidomide therapy may occasionally benefit recalcitrant
RAS.190
Pentoxifylline
Results of limited open studies suggest that pentoxifylline (400 mg three times daily) may significantly reduce
the number of RAS for up to 9 months after a month of
therapy.191195 The results of a recent study, however,
did not confirm that pentoxifylline reduces the recurrence of RAS when therapy is stopped.196 About 10% of
patients will have some degree of gastrointestinal upset
with pentoxifylline therapy.
Dapsone
Dapsone has been reported to reduce the oral lesions in
a few patients with RAS-like lesions, but the clinical
features of this group of patients were poorly described.197
Clinics in Dermatology
2000;18:569 578
Thalidomide
Thalidomide remains the most effective agent for the
management of RAS, producing a remission in almost
50% of treated patients in one randomized controlled
trial.198 Open and double-blind studies of patients with
HIV-related oral ulceration199,200 and in non-HIV-related RAS,201 and in several case studies, all confirm
that thalidomide is of clinical benefit.202204 Thalidomide gives rise to mild adverse side effects (eg, intolerance, loss of libido) in up to 75% of treated patients,
and polyneuropathy can arise in about 5% of cases.
Clearly the risk of teratogenicity also limits the clinical
application of thalidomide in the management of RAS.
Other Agents
Transfer factor205 and gammaglobulin therapy206 have
been suggested to be beneficial, but more detailed studies are needed to confirm these preliminary observations.
The reported clinical benefit of monoamine oxidase
inhibitor therapy in the treatment of three patients with
RAS207,208 was probably due to accompanying dietary
modifications rather than any alteration in psychological status.
8.
9.
10.
11.
12.
13.
14.
15.
16.
Conclusions
Recurrent aphthous stomatitis remains a common oral
mucosal disorder in most communities of the world;
however, as its precise etiology (or etiologies) remains
unknown, therapy is nonspecific and often of limited
efficacy. Fortuitously, patients with RAS are generally
otherwise quite well.
17.
References
20.
18.
19.
21.
22.
23.
24.
25.
26.
573
of the oral mucosa in children in light of own observations. Czas Stomatol 1971;24:8715.
Peretz B. Major recurrent aphthous stomatitis in an 11year-old girl: Case report. J Clin Pediat Dent 1994;18:
309 11.
Crevelli MR, Aguas S, Adler I, et al. Influence of socioeconomic status on oral mucosa lesion prevalence in
schoolchildren. Community Dent Oral Epidemiol 1988;
16:58 60.
Porter SR, Scully C. Aphthous stomatitisan overview
of aetiopathogenesis and management. Clin Exp Dermatol 1991;16:235 43.
International Study Group for Behcets Disease. Criteria for diagnosis of Behcets disease. Lancet 1990;335:
1078 80.
Krause I, Rosen Y, Kaplan I, et al. Recurrent aphthous
stomatitis in Behcets disease: Clinical features and correlation with systemic disease expression and severity.
J Oral Pathol Med 1999;28:193 6.
Rogers R. Recurrent aphthous stomatitis in the diagnosis
of Behcets disease. Yonsei Med J 1997;38:370 9.
Lee S. Diagnostic criteria of Behcets disease: Problems
and suggestions. Yonsei Med J 1997;38:3659.
Krause I, Uziel Y, Guedj D, et al. Mode of presentation
and multisystem involvement in Behcets disease: The
influence of sex and age of disease onset. J Rheumatol
1998;25:1566 9.
von den Driesch P. Sweets syndrome (acute febrile
neutrophilic dermatosis). J Am Acad Dermatol 1994;
31:53559.
von den Driesch P, Schlegel GR, Kiesewetter F, et al.
Sweets syndrome: Clinical spectrum and associated conditions. Cutis 1989;44:193200.
Driban NE, Alvarez MA. Oral manifestations of Sweets
syndrome. Dermatologica 1984;169:1023.
Lange RD, Jones JB. Cyclic neutropenia: A review of
clinical manifestations and management. Ann J Pediat
Haematol Oncol 1981;3:3637.
Scully C, MacFadyen EE, Campbell A. Orofacial manifestations in cyclic neutropenia. Br J Oral Surg 1982;20:
96 101.
Sucker C, Djawari D. Rezidivierede Gingivostomatitis
ulcerosa bei zyklischer Neutropenie. Hautarzt 1999;50:
503 6.
Porter SR, Scully C, Standen GR. Oral ulceration as a
manifestation of autoimmune neutropenia. Oral Surg
Oral Med Oral Pathol 1994;78:179 80.
Hasturk H, Tezcan I, Yel L, et al. A case of chronic severe
neutropenia: Oral findings and consequences of shortterm granulocyte colony-stimulating factor treatment.
Aust Dent J 1998;43:9 13.
Orme RL, Nordlund JJ, Barich L, et al. The MAGIC
syndrome (mouth and genital ulcers with inflammed
cartilage). Arch Dermatol 1990;126:940 4.
Le Thi Huong D, Wechsler B, Piette JC, et al. Aortic
insufficiency and recurrent valve prosthesis dehiscence
in MAGIC syndrome. J Rheumatol 1993;20:397 8.
Marshall GS, Edwards KM, Butler J, et al. Syndrome of
periodic fever, pharyngitis and aphthous stomatitis. J Pediatr 1987;110:43 6.
Clinics in Dermatology
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
2000;18:569 578
thous ulceration: Vitamin B1, B2 and B6 status and response to replacement therapy. J Oral Path Med 1991;20:
389 91.
Ferguson R, Basu MK, Asquith P, et al. Jejunal mucosal
abnormalities in patients with recurrent aphthous ulceration. Br Med J 1976;1:113.
Ferguson MM, Wray D, Carmichael HA, et al. Coeliac
disease associated with recurrent aphthae. Gut 1980;21:
223 6.
Velso FT, Saleiro JV. Small-bowel changes in recurrent
ulceration of the mouth. Hepatogastroenterology 1987;
34:36 7.
Merchant NE, Ferguson MM, Ali A, et al. The detection
of IgA-reticulin antibodies and their incidence in patients with recurrent aphthae. J Oral Med 1986;41:31 4.
OMahony C, OFarrelly C, Weir DG, et al. Gluten-sensitive oral ulceration in the absence of coeliac disease.
Gut 1985;26:A1137.
Meini A, Pillan MN, Plebani A, et al. High prevalence of
DRW10 and DQW1 antigens in celiac disease associated
with recurrent aphthous stomatitis. Am J Gastroenterol
1993;88:972.
Wray D. Gluten-sensitive recurrent aphthous stomatitis.
Dig Dis Sci 1981;26:737 40.
Wright A, Ryan FP, Willingham SE, et al. Food allergy or
intolerance in severe recurrent aphthous ulceration of
the mouth. Br Med J 1986;292:1237 8.
Hunter IP, Ferguson MM, Scully C, et al. Effects of
dietary gluten elimination in patients with recurrent minor aphthous stomatitis and no detectable gluten enteropathy. Oral Surg Oral Med Oral Pathol 1993;75:595 8.
Robinson N, Porter SR. Lack of detection of anti-endomysial antibodies in recurrent aphthous stomatitis.
(Manuscript in preparation).
Rehberger A, Puspok A, Stallmeister T, et al. Crohns
disease masquerading as aphthous ulcers. Eur J Dermatol 1998;8:274 6.
Tuft L, Ettleson LN. Canker sores from allergy to weak
organic acids (citric and acetic). J Allergy 1956;27:536 43.
Wilson CWM. Food sensitivities, taste changes, aphthous ulcers and atopic symptoms in allergic disease.
Ann Allergy 1980;44:3027.
Spouge JD, Diamond HF. Hypersensitivity reactions in
mucous membranes. 1. The statistical relationship between hypersensitivity diseases and recurrent oral ulcerations. Oral Surg 1963;16:41221.
Eversole LR, Shopper TP, Chambers DW. Effects of suspected foodstuff challenging agents in the aetiology of
recurrent aphthous stomatitis. Oral Surg 1983;56:33 8.
Wray D, Vlagopoulos TP, Siraganian RP. Food allergens
and basophil histamine release in recurrent aphthous
stomatitis. Oral Surg 1982;54:388 95.
Hay D, Reade PC. The use of an elimination diet in the
treatment of recurrent aphthous ulceration of the oral
cavity. Oral Surg 1984;57:504 7.
Endre L. Recurrent aphthous ulceration with zinc deficiency and cellular immune deficiency. Oral Surg Oral
Med Oral Pathol 1991;72:559 61.
Dolby AE. Recurrent Mikuliczs oral aphthaetheir relationship to the menstrual cycle. Br Dent J 10968;124:
359 60.
Clinics in Dermatology
2000;18:569 578
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
575
Clinics in Dermatology
105. Ship II, Ashe WK, Scherp HW. Recurrent fever blister
and canker sore. Tests for herpes simplex and other
viruses with mammalian cell cultures. Arch Oral Biol
1961;3:11724.
106. Eglin RP, Lehner T, Subak-Sharpe JH. Detection of RNA
complimentary to herpes simplex virus in mononuclear
cells from patients with Behcets syndrome and recurrent
oral ulcers. Lancet 1982;2:1356 61.
107. Hussain L, Ward R, Lehner T, et al. Herpes simplex virus
IgG, IgM and IgA subclass from sera of patients with
Behcets disease and controls. In: Lehner T, Barnes CG,
editors. Recent advances in Behcets disease. London:
Royal Society of Medicine, 1986:737.
108. Hooks JJ, Moutsopoulos HM, Geiss A, et al. Immune
interferon in the circulation of patients with autoimmune
disease. N Engl J Med 1979;301:508.
109. Galliani EA, Infantolino D, Tarantello M, et al. Stomatite
aftosa ricorrente: Quale ruolo per I virus, gli alimenti ed
I materiali odontoiatrici? Ann Ital Med Int 1998;13:152 6.
110. Studd M, McCance DJ, Lehner T. Detection of HSV-1
DNA in patients with Behcets syndrome and in patients
with recurrent oral ulcers by the polymerase chain reaction. J Med Microbiol 1991;34:39 43.
111. Ship II, Brightman VJ, Laster LL. The patient with recurrent aphthous ulcers and the patient with recurrent herpes labialis: A study of two population samples. J Am
Dent Assoc 1967;75:64554.
112. Pedersen A, Hornsleth A. Recurrent aphthous ulceration: A possible clinical manifestation of reactivation of
varicella zoster or cytomegalovirus infection. Oral Pathol
Med 1993;22:64 8.
113. Pedersen A, Madsen HO, Faber V, et al. Varicella-zoster
virus DNA in recurrent aphthous ulcers. Scand J Dent
Res 1993;101:3113.
114. Godratnama F, Wray D, Bagg J. Detection of serum
antibodies against cytomegalovirus, varicella zoster virus and human herpesvirus-6 in patients with recurrent
aphthous stomatitis. J Oral Pathol Med 1999;28:125.
115. Godratnama F, Riggio MP, Wray D. Search for human
herpesvirus-6, human cytomegalovirus and varicella
zoster virus DNA in recurrent aphthous stomatitis tissue. J Oral Pathol Med 1997;26:1927.
116. Wormser GP, Mack L, Lenox T, et al. Lack of effect of
oral acyclovir on prevention of aphthous stomatitis. Otolaryngol Head Neck Surg 1988;98:14 7.
117. Pedersen A. Acyclovir in the prevention of severe aphthous ulcers. Arch Dermatol 1992;128:119 20.
118. Sun A, Chang J-G, Chu C-T, et al. Preliminary evidence
for an association of Epstein-Barr virus with pre-ulcerative oral lesions in patients with recurrent aphthous
ulcers or Behcets disease. J Oral Pathol Med 1998;27:
168 75.
119. Brice S, Cook D, Leahy M, et al. Examination of the oral
mucosa and peripheral blood cells of patients with recurrent aphthous ulceration for human herpesvirus
DNA. Oral Surg Oral Med Oral Pathol Oral Radiol
Endod 2000;89:193 8.
120. Ross R, Kutscher AH, Zegarelli EV, et al. Relationship of
mechanical trauma to recurrent ulcerative (aphthae) stomatitis. NY State Dent J 1958;24:1012.
121. Wray D, Graykowski EA, Notkins AL. Role of mucosal
122.
123.
124.
125.
126.
127.
128.
129.
130.
131.
132.
133.
134.
135.
136.
137.
138.
139.
140.
141.
2000;18:569 578
Clinics in Dermatology
142.
143.
144.
145.
146.
147.
148.
149.
150.
151.
152.
153.
154.
155.
156.
157.
158.
159.
160.
2000;18:569 578
161.
162.
163.
164.
165.
166.
167.
168.
169.
170.
171.
172.
173.
174.
175.
176.
177.
178.
577
Clinics in Dermatology
2000;18:569 578